Hodinový prehľad - Zdravotnícke a vedecké zaujímavosti

Vygenerované: 25.06.2026 14:32:15

Does denmark meet who target for flu vaccination in t1d

Zdroj: Medscape

URL: https://www.medscape.com/viewarticle/does-denmark-meet-world-health-organization-target-flu-2026a1000l82?src=rss

Súhrn:

Súhrn: TOPLINE: In Denmark, influenza vaccination coverage among patients with type 1 diabetes (T1D) remained well below the World Health Organization target of 75% throughout 2015-2022, reaching only 16 METHODOLOGY: - Researchers conducted a register-based cohort study in Denmark to evaluate influenza vaccine coverage, persistence across multiple seasons, and factors associated with non-vaccination among patients with T1D 3% across study groups.

Dovetok:

Doplnenie: Lower vaccination rates among adults were associated with insufficient glycaemic control, male sex, and educational attainment of less than 15 years.

Do involuntary admissions affect clinicians duševný zdravie

Zdroj: Medscape

URL: https://www.medscape.com/viewarticle/do-involuntary-admissions-affect-clinicians-mental-health-2026a1000ln0?src=rss

Súhrn:

Súhrn: A Spanish study explored how these interventions affect both patients and healthcare professionals Out-of-hospital emergency medical professionals frequently encounter situations in which involuntary admission to a healthcare facility is necessary In these exceptional circumstances and in accordance with current healthcare legislation, coercive measures may be required when an individual lacks the capacity to provide informed consent or poses a risk to themselves or others.

Dovetok:

Doplnenie: In these exceptional circumstances and in accordance with current healthcare legislation, coercive measures may be required when an individual lacks the capacity to provide informed consent or poses a risk to themselves or others.

Can bimekizumab match il 23 inhibitors in psoriasis

Zdroj: Medscape

URL: https://www.medscape.com/viewarticle/can-bimekizumab-match-il-23-inhibitors-drug-survival-after-2026a1000l80?src=rss

Súhrn:

Súhrn: TOPLINE: In a retrospective study, switching to bimekizumab after the failure of secondary interleukin (IL)-17 inhibitors demonstrated comparable drug survival to switching to IL-23 inhibitors in patients with psoriasis METHODOLOGY: - Researchers conducted a retrospective evaluation of 127 patients with psoriasis who discontinued an IL-17 inhibitor due to secondary failure and were directly switched to either bimekizumab or an IL-23 inhibitor - A total of 38 patients were switched to bimekizumab (intraclass switch), whereas 89 patients were switched to IL-23 inhibitors including guselkumab (n = 26) and risankizumab (n = 63), with IL-23 inhibitors analysed together as one group.

Dovetok:

Doplnenie: - The primary outcome was drug survival.